[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351679-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351679-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","evaluating-the-impact-of-glp-1-receptor-agonists-in-combination-with-total-neoadjuvant-therapy-for-locally-advanced-rectal-cancer","Evaluating the impact of GLP-1 receptor agonists in combination with total neoadjuvant therapy for locally advanced rectal cancer","","Total neoadjuvant therapy (TNT) has become a standard treatment approach for rectal cancer, providing higher rates of pathological complete response and improved long-term survival. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated advantages in weight loss, systemic metabolic regulation, and anti-inflammatory effects. This narrative review examines the biological rationale and potential therapeutic benefits of combining GLP-1 RAs with TNT for locally advanced rectal cancer. It reviews preclinical and clinical evidence on effects of GLP-1–induced metabolic changes on tumour biology, treatment tolerance, and outcomes in vulnerable patients.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/evaluating-the-impact-of-glp-1-receptor-agonists-in-combination-with-total-neoadjuvant-therapy-for-locally-advanced-rectal-cancer/351679/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/evaluating-the-impact-of-glp-1-receptor-agonists-in-combination-with-total-neoadjuvant-therapy-for-locally-advanced-rectal-cancer/351679.png","ImageObject",300,407,{"name":42,"@type":43},"Cart","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of this narrative review?","Question",{"text":63,"@type":64},"To evaluate the biological basis and potential therapeutic benefits of combining GLP-1 receptor agonists with total neoadjuvant therapy for locally advanced rectal cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why are GLP-1 receptor agonists considered in rectal cancer treatment?",{"text":68,"@type":64},"They may influence tumour biology and treatment tolerance through effects on visceral fat, insulin resistance, and systemic inflammation, with observational data suggesting reduced obesity-related cancer incidence.",{"name":70,"@type":61,"acceptedAnswer":71},"What treatment context does the review focus on?",{"text":72,"@type":64},"Locally advanced rectal cancer managed with total neoadjuvant therapy followed by total mesorectal excision, highlighting improved survival and pathological complete response rates.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351679,1790459303,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","BJS, 2026, znag029  \n[https://doi.org/10.1093/bjs/znag029](https://doi.org/10.1093/bjs/znag029)  \nCutting Edge Review  \nEvaluating the impact of GLP-1 receptor agonists in combination with total neoadjuvant therapy for locally advanced rectal cancer  \nHugo C. Temperley1,2,3,*†, Matthew Coalter4,† , Ben Creavin3,5 , Patrick Jordan3 , Andrew Hogan6, Jacintha O’Sullivan2,7, Donal O’Shea8, Paul H. McCormick3, Emily Harrold9 and Michael E. Kelly2,3,7   \n1Department of Radiology, St. James’s Hospital, Dublin, Ireland  \n2Trinity St. James’s Cancer Institute, St. James’s Hospital, Dublin 8, Ireland 3Department of Surgery, St. James’s Hospital, Dublin 8, Ireland 4Department of Immunology, St. James’s Hospital, Dublin, Ireland  \n5Department of Surgery, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia 6Obesity Immunology Research Group, Maynooth University, Maynooth, Ireland  \n7School of Medicine, Trinity College Dublin, Dublin 2, Ireland  \n8Department of Endocrinology, St Vincent’s University Hospital, Dublin 4, Ireland 9Department of Medical Oncology, St. James’s Hospital, Dublin 8, Ireland  \n*Correspondence to: Hugo C. Temperley, Trinity St. James’s Cancer Institute, St. James’s Hospital, Dublin 8, Ireland (e-mail: [temperlh@tcd.ie](temperlh@tcd.ie))  \n†These authors contributed equally to this work.  \nAbstract  \nTotal neoadjuvant therapy (TNT) has become a standard treatment approach for rectal cancer, providing higher rates of pathological complete response and improved long-term survival. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown significant advantages in weight loss, systemic metabolic regulation, and anti-inflammatory effects. Emerging evidence also points to possible anticancer properties, with observational data suggesting a lower incidence of obesity-related cancers, including colorectal cancer. This narrative review aims to examine the biological basis and potential therapeutic benefits of combining GLP-1 RAs with TNT for the management of locally advanced rectal cancer. We explore how GLP-1 RAs may affect tumour biology and treatment tolerance, including their impact on visceral fat, insulin resistance, and systemic inflammation. Preclinical and clinical data are reviewed to determine whether GLP-1-induced metabolic changes can improve the effectiveness of chemotherapy and enhance surgical and oncological results. Although evidence is evolving, the integration of GLP-1 receptor agonists into rectal cancer treatment pathways represents a promising area for further investigation, particularly in metabolically vulnerable populations.  \nIntroduction  \nRectal cancer comprises approximately 30–40% of colorectal adenocarcinoma, the third most common solid organ malignancy worldwide1. One-third of this is locally advanced rectal cancer (LARC)2 , defined as disease that has invaded through the muscularis propria up to but not beyond the rectal serosa (T3), or through the wall of the rectum into adjacent organs (T4), and/or involving mesorectal lymph nodes in the absence of metastatic disease3. The current guidelines in the UK and Ireland4 , Europe5 , and the United States3 are to treat locally advanced rectal cancer with total neoadjuvant chemoradiotherapy (TNT) followed by total mesorectal excision (TME)6. TNT has been shown to improve overall survival (OS) and disease-free survival (DFS), increase the pathological complete response rate (pCR), reduce toxicity, improve treatment adherence, and increase sphincter preservation7–10.  \nObesity is a recognized negative prognostic factor in colorectal cancer, with affected patients demonstrating poorer clinical outcomes11. Patients with obesity have higher rates of all-cause  \nmorbidity (43% versus 21%)12 , as well as higher rates of recurrence13. Weight loss prior to surgery has been proposed to mitigate these risks by improving patients’ functional status. Traditionally, a structured approach to weight loss with aprehabilitation programme of ex","cbCaibRAb0Tr9fEa","https://ap.wps.com/l/cbCaibRAb0Tr9fEa","pdf",1816058,"English","# Abstract\n# Introduction\n# Methodology","[{\"question\":\"What is the main purpose of this narrative review?\",\"answer\":\"To evaluate the biological basis and potential therapeutic benefits of combining GLP-1 receptor agonists with total neoadjuvant therapy for locally advanced rectal cancer.\"},{\"question\":\"Why are GLP-1 receptor agonists considered in rectal cancer treatment?\",\"answer\":\"They may influence tumour biology and treatment tolerance through effects on visceral fat, insulin resistance, and systemic inflammation, with observational data suggesting reduced obesity-related cancer incidence.\"},{\"question\":\"What treatment context does the review focus on?\",\"answer\":\"Locally advanced rectal cancer managed with total neoadjuvant therapy followed by total mesorectal excision, highlighting improved survival and pathological complete response rates.\"}]","Evaluating the impact of GLP-1 receptor agonists in combination with total neoadjuvant therapy for locally advanced rectal cancer | PDF",1790095252,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0093223de04740e9944761d96c2b8dba.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a07c87c8c90036acc010b836b2d27f6.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/debaba60d400bc0fe201831f8db3e075.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/500a88f517832024f7e69e621401faec.webp",980,1287]